CinDome Pharma

Executive Summary

CinDome Pharma, a privately held biopharmaceutical company and a portfolio company of CinRx, is focused on addressing the unmet medical need in chronic gastroparesis. Its lead candidate, deudomperidone (CIN-102), is a novel, peripherally selective dopamine D2 receptor antagonist designed to enhance gastric motility while minimizing central nervous system side effects. The drug is currently in Phase 3 clinical development, targeting a condition characterized by delayed gastric emptying without mechanical obstruction, often seen in diabetic and idiopathic patients. Current treatment options are limited, with metoclopramide carrying black-box warnings and domperidone restricted due to cardiac safety concerns. Deudomperidone aims to offer improved efficacy and safety, leveraging deuterium modification to potentially reduce QT prolongation risk. Given the significant patient population and lack of approved therapies beyond metoclopramide, CinDome's asset could fill a critical gap. The company's near-term focus is on advancing the Phase 3 program, with potential registrational data readouts that could support an NDA submission. Success in this pivotal trial would position CinDome as a leader in gastroparesis therapy and likely attract partnership or acquisition interest.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Top-Line Data Readout for Deudomperidone (CIN-102)60% success
• H1 2027Initiation of NDA Submission or Pre-NDA Meeting50% success
• Q2 2027Potential Partnership or Licensing Deal40% success